Diabetic Macular Edema Clinical Trial
— GLIMMEROfficial title:
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
Verified date | September 2023 |
Source | Kodiak Sciences Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
Status | Terminated |
Enrollment | 459 |
Est. completion date | August 31, 2023 |
Est. primary completion date | April 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent prior to participation in the study. 2. Treatment-naïve diabetic macular edema, with vision loss and center involvement (if present) diagnosed within 9 months of screening. 3. BCVA ETDRS letter score between 78 and 25 (-20/25 to 20/320 Snellen equivalent), inclusive, in the Study Eye. 4. CST of = 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT instruments) as determined by the Reading Center. 5. Decrease in vision determined by the Investigator to be primarily the result of DME. 6. Type 1 or Type 2 diabetes mellitus and a HbA1c of =12%. 7. Other protocol-specified inclusion criteria may apply. Exclusion Criteria: 1. Macular edema in the Study Eye considered to be secondary to a cause other than DME. 2. Active iris or angle neovascularization or neovascular glaucoma in the Study Eye. 3. High-risk proliferative diabetic retinopathy characteristics in the Study Eye. 4. History of Pan-retinal Photocoagulation (PRP) laser in the Study Eye within 3 months of screening. 5. Tractional retinal detachment in the Study Eye. 6. Active retinal disease other than the condition under investigation in the Study Eye. 7. Any history or evidence of a concurrent ocular condition present, that in the opinion of the Investigator could require either medical or surgical intervention or affect macular edema or alter visual acuity during the study (e.g., vitreomacular traction, epiretinal membrane). 8. Active or suspected ocular or periocular infection or inflammation in either eye at Day 1. 9. Any prior use of an approved or investigational treatment for DME in the Study Eye (e.g., anti-VEGF, intraocular or periocular steroids, macular laser photocoagulation). 10. Women who are pregnant or lactating or intending to become pregnant during the study. 11. Uncontrolled blood pressure defined as a systolic value = 180 mmHg or diastolic value =100 mmHg while at rest. 12. Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event. 13. History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product. 14. Other protocol-specified exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Czechia | OFTEX s.r.o. | Pardubice | |
Czechia | Lekarna BENU | Praha | |
Czechia | Vseobecna Fakultni | Praha | |
France | Centre Hospitalier Intercommunal de Créteil | Créteil | |
France | CHRU Dijon Complexe Du Bocage | Dijon | Côte-d'Or |
France | Hôpital de La Croix Rousse | Lyon | Rhône |
France | Centre Paradis Monticelli | Marseille | |
France | Fondation Rothschild | Paris | |
France | Hôpital Lariboisière - Service Pharmacie , Essais cliniques - Aude Jacob | Paris | |
Hungary | Bajcsy-Zsilinszky Korhaz es Rendelointezet | Budapest | |
Hungary | Budapest Retina Associates Kft | Budapest | |
Hungary | Semmelweis Egyetem | Budapest | |
Hungary | Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz , Josa Andras Oktatókórház | Nyíregyháza | Szabolcs-Szatmár-Bereg |
Israel | Bnai Zion | Haifa | |
Israel | Rambam MC | Haifa | |
Israel | Hadassah University Hospital | Jerusalem | |
Israel | Meir MC | Kfar Saba | |
Israel | Rabin Medical Center | Petach Tikva | |
Israel | Kaplan MC | Rehovot | |
Israel | Assuta HaShalom | Tel Aviv | |
Israel | Tel Aviv Sourasky Medical Center | Tel Aviv | |
Israel | Shamir Medical Center Assaf Harofeh | Tzrifin | |
Italy | Ospedale San Raffaele S.r.l. - PPDS | Milano | Lombardia |
Italy | AOU dell'Università degli Studi della Campania Luigi Vanvitelli | Naples | |
Italy | Fondazione Policlinico Universitario A Gemelli | Roma | Lazio |
Poland | Oftalmika Sp. z o.o. | Bydgoszcz | |
Poland | Optimum Profesorskie Centrum Okulistyki | Gdansk | Pomorskie |
Poland | Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowi | Katowice | Slaskie |
Poland | Specjalistyczny Szpital im. Alfreda Sokolowskiego | Walbrzych | |
Poland | Dr Nowosielska Okulistyka i Chirurgia Oka | Warszawa | |
Poland | Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu | Wroclaw | |
Puerto Rico | Emanuelli Research & Development Center LLC | Arecibo | |
United States | Retina Consultants of Hawaii, Inc | 'Aiea | Hawaii |
United States | Retina Research Institute of Texas | Abilene | Texas |
United States | Asheville Eye Associates | Asheville | North Carolina |
United States | Southeast Retina Center | Augusta | Georgia |
United States | Austin Research Center for Retina | Austin | Texas |
United States | Retina Vitreous Associates | Beverly Hills | California |
United States | Retina Specialists of Idaho | Boise | Idaho |
United States | Florida Eye Microsurgical Institute | Boynton Beach | Florida |
United States | Cleveland Clinic Foundation, Cole Eye Institute | Cleveland | Ohio |
United States | Rand Eye Institute | Deerfield Beach | Florida |
United States | Talley Eye | Evansville | Indiana |
United States | National Ophthalmic Research Institute | Fort Myers | Florida |
United States | Texas Retina Associates | Fort Worth | Texas |
United States | Retina Consultants of Orange County | Fullerton | California |
United States | Vitreo Retinal Consultants | Hauppauge | New York |
United States | Retina Consultants of NV | Henderson | Nevada |
United States | Retina Consultants of Houston-(Katy) | Katy | Texas |
United States | Southeastern Retina Associates PC | Knoxville | Tennessee |
United States | Retina-Vitreous Surgeons of Central NY | Liverpool | New York |
United States | Georgia Retina, P.C. | Marietta | Georgia |
United States | Vitreoretinal Surgery PA | Minneapolis | Minnesota |
United States | Northern California Retina Vitreous Associates | Mountain View | California |
United States | Ophthalmic Consultants of Long Island | Oceanside | New York |
United States | Retinal Research Institute, LLC | Phoenix | Arizona |
United States | Texas Retina Associates | Plano | Texas |
United States | Fort Lauderdale Eye Institute | Plantation | Florida |
United States | Maine Eye Center | Portland | Maine |
United States | Retina Consultants of San Diego | Poway | California |
United States | Sierra Eye Associates | Reno | Nevada |
United States | Retina Institute of Virginia | Richmond | Virginia |
United States | Retina Associates of Western NY | Rochester | New York |
United States | Austin Retina Associates (Round Rock) | Round Rock | Texas |
United States | Associated Retinal Consultants PC | Royal Oak | Michigan |
United States | Retinal Consultants Medical Group Inc | Sacramento | California |
United States | Retina Vitreous Associates of Florida | Saint Petersburg | Florida |
United States | Retina Consultants, LLC | Salem | Oregon |
United States | Medical Center Ophthalmology Associates | San Antonio | Texas |
United States | Southern Vitreoretinal Associates | Tallahassee | Florida |
United States | Retina Consultants of Houston - (Woodlands) | The Woodlands | Texas |
United States | Retina Group of New England | Waterford | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Kodiak Sciences Inc |
United States, Czechia, France, Hungary, Israel, Italy, Poland, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-inferiority of KSI-301 to Aflibercept measured by changes in BCVA. | Demonstrate that KSI-301 5 mg is non-inferior to aflibercept 2 mg with respect to mean change in best corrected visual acuity (BCVA). | Day 1 to Year 1 | |
Secondary | Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in BCVA. | Improvement in best corrected visual acuity (BCVA). | Day 1 to Year 2 | |
Secondary | Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in CST. | Improvement in central subfield thickness (CST). | Day 1 to Year 2 | |
Secondary | Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in DRSS. | Improvement if the diabetic retinopathy severity score (DRSS). | Day 1 to Year 2 | |
Secondary | Durability of KSI-301 5 mg compared to aflibercept 2 mg measured by number of intravitreal injections during the study. | Mean number of intravitreal injections during the course of the study. | Day 1 to Year 2 | |
Secondary | Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events. | Incidence of ocular and systemic adverse events. | Day 1 to Year 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 | |
Active, not recruiting |
NCT00801450 -
Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery
|
Phase 1/Phase 2 |